Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
Z. Ping Lin, Yong-Lian Zhu, Ying‐Chun Lo, et al.
PLoS ONE (2018) Vol. 13, Iss. 11, pp. e0207399-e0207399
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Targeting iron metabolism in cancer therapy
Michael J. Morales, Xiang Xue
Theranostics (2021) Vol. 11, Iss. 17, pp. 8412-8429
Open Access | Times Cited: 160
Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
Patrycja Gralewska, Arkadiusz Gajek, Agnieszka Marczak, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 64
Impact of hypoxia on DNA repair and genome integrity
Alanna R. Kaplan, Peter M. Glazer
Mutagenesis (2019) Vol. 35, Iss. 1, pp. 61-68
Open Access | Times Cited: 61
Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer
Yijun Xie, Di Xiao, Duo Li, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 6
Iron chelators in cancer therapy
Ola Ibrahim, Jeff O’Sullivan
BioMetals (2020) Vol. 33, Iss. 4-5, pp. 201-215
Closed Access | Times Cited: 47
Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1
Sergio Corrales-Guerrero, Tiantian Cui, Verónica Castro-Aceituno, et al.
Cancer Letters (2023) Vol. 570, pp. 216308-216308
Closed Access | Times Cited: 13
PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality—An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness
Patrycja Gralewska, Arkadiusz Gajek, Agnieszka Marczak, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 24, pp. 9715-9715
Open Access | Times Cited: 29
Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises
Aikaterini Skorda, Marie Lund Bay, Sampsa Hautaniemi, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6257-6257
Open Access | Times Cited: 17
Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines
Patrycja Gralewska, Arkadiusz Gajek, Agnieszka Marczak, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10557-10557
Open Access | Times Cited: 21
Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review)
Ning Jin, Yu Xia, Qinglei Gao
International Journal of Oncology (2023) Vol. 62, Iss. 2
Open Access | Times Cited: 7
Exploiting replicative stress in gynecological cancers as a therapeutic strategy
Natalie Ngoi, Vignesh Sundararajan, David S.P. Tan
International Journal of Gynecological Cancer (2020) Vol. 30, Iss. 8, pp. 1224-1238
Open Access | Times Cited: 20
Reversing oncogenic transformation with iron chelation
Gina Abdelaal, Stephany Veuger
Oncotarget (2021) Vol. 12, Iss. 2, pp. 106-124
Open Access | Times Cited: 17
Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells
Aleksandra Romaniuk, Paulina Skupin-Mrugalska, Olga B. Garbuzenko, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
H2A Histone Family Member X (H2AX) Is Upregulated in Ovarian Cancer and Demonstrates Utility as a Prognostic Biomarker in Terms of Overall Survival
Sayeh Saravi, Eriko Katsuta, Jeyarooban Jeyaneethi, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 9, pp. 2844-2844
Open Access | Times Cited: 15
Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
Ruihong Dong, Ting Ding, Zhengyu Li
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 5
Potential Therapeutic Targets in Ovarian Cancer: Autophagy and Metabolism
Misung Park, Soohyun Choe, Miyoung Shin, et al.
Frontiers in Bioscience-Landmark (2023) Vol. 28, Iss. 3, pp. 47-47
Open Access | Times Cited: 4
Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild Type Ovarian Cancer Cells to Olaparib
Cai M. Roberts, Mehida Rojas-Alexandre, Ruth E. Hanna, et al.
(2023)
Open Access | Times Cited: 4
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints
S. Percy Ivy, Charles A. Kunos, Fernanda I. Arnaldez, et al.
Expert Opinion on Investigational Drugs (2019) Vol. 28, Iss. 9, pp. 771-785
Closed Access | Times Cited: 11
Synergy trap for guardian angels of DNA: Unraveling the anticancer potential of phthalazinone-thiosemicarbazone hybrids through dual PARP-1 and TOPO-I inhibition
Eman M Elkafoury, Mervat H. El‐Hamamsy, Eman A. El-Bastawissy, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107924-107924
Closed Access | Times Cited: 1
Pharmacological methods to transcriptionally modulate double-strand break DNA repair
Alanna R. Kaplan, Peter M. Glazer
International review of cell and molecular biology (2019), pp. 187-213
Open Access | Times Cited: 9
In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer
Z. Ping Lin, Nour N. Al Zouabi, Mark L. Xu, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 8
Puzzling out iron complications in cancer drug resistance
Marjan Abedi, Soheila Rahgozar
Critical Reviews in Oncology/Hematology (2022) Vol. 178, pp. 103772-103772
Closed Access | Times Cited: 6
Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib
Cai M. Roberts, Mehida Rojas-Alexandre, Ruth E. Hanna, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3919-3919
Open Access | Times Cited: 3
Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents
Elizabeth K. Lee, Joyce F. Liu
Cancer treatment and research (2023), pp. 171-188
Closed Access | Times Cited: 3
Inhibition of Ribonucleotide Reductase Induces Endoplasmic Reticulum Stress and Apoptosis, Leading to the Death of Docetaxel-resistant Prostate Cancer Cells
Rıza Serttas, Suat Erdoğan
Anti-Cancer Agents in Medicinal Chemistry (2023) Vol. 23, Iss. 17, pp. 1958-1965
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top